Evvy, a female-founded startup unlocking precision women’s healthcare through biomarker discovery, announced today the closing of a $14 million Series A funding round led by Left Lane Capital. The round also includes General Catalyst, Labcorp […]
Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis for neurological diseases, today announced positive results from its Phase 1 clinical study […]
Bactolife A/S (“Bactolife”), a bioindustrial company developing proprietary Binding ProteinsTM, which strengthen the gut microbiome of humans and animals with the aim of reducing the burden of gastrointestinal infections and anti-microbial resistance, today announced that […]
The Dutch government has reserved €200 million from its National Growth Fund for the establishment of the Holomicrobiome Institute and its activities during the first ten years. The reservation was announced by Minister Adriaansens of […]
Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, […]
Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, announced the completion of its €24 million ($26 million) Series A with a last extension […]
Pendulum Therapeutics, the biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announced a strategic partnership with New Zealand dairy nutrition company Fonterra. Fonterra will invest $10 million into the growth-stage […]
The new biotech venture PHIOGEN is a spin-off company from Baylor College of Medicine’s TAILOR Labs, one of the United States only academic phage therapy cores with a decade’s worth of revolutionary research related to bacteriophages, viruses that infect […]
Azitra, Inc. (NYSE American: AZTR) (the “Company”), a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products, today announced the closing of its initial public offering of […]
Metagen Therapeutics, a company focusing on drug discovery and development based on intestinal microbiome-based therapeutics for various diseases, has completed its Series A funding in 2 rounds, raising a total of 1.7 billion yen. Sparx […]
Verb Biotics LLC., a microbiome innovation company, today announced that they have acquired YSOPIA Bioscience’s strain and IP portfolio targeted for human health and wellness. The acquisition of YSOPIA’s strain portfolio includes one of the […]